Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 322-328

  Meyer Rath, Gesine ^a,b   Brennan, Alana T ^a,b   Fox, Matthew P ^a,b   Modisenyane, Tebogo ^c   Tshabangu, Nkeko ^c   Mohapi, Lerato ^c   Rosen, Sydney ^a,b   Martinson, Neil ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Admission; Hospitalization; Inpatient; Pre ART; Resource limited setting

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HEADACHE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LENGTH OF STAY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RURAL AREA; SOUTH AFRICA; URBAN AREA;

EID: 85027918843     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827e8785     Document Type: Article

References (42)

1. Beck EJ, Mandalia S, Griffith R, et al. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre. Pharmacoeconomics 2000;17:53-69.
2. Baum SE, Morris JT, Gibbons RV, et al. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Mil Med 1999; 164:609-612.
3. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-F105.
4. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4, 200 cells/microL) with HIV infection. HIV Med 2004;5:93-98.
5. Nykamp D, Barnett CW, Lago M, et al. Cost of medication therapy in ambulatory HIV-infected patients. Ann Pharmacother. 1997;31:303-307.
6. Krentz HB, Auld MC, Gill MJ. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ. 2003;169:106-110.
7. Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001;13:733-741.
8. Stoll M, Claes C, Schulte E, et al. Direct costs for the treatment of HIVinfection in a German cohort after the introduction of HAART. Eur J Med Res. 2002;7:463-471.
9. Kyriopoulos JE, Geitona MA, Paparizos VA, et al. The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece. J Med Syst. 2001;25:73-80.
10. Sendi PP, Craig BA, Meier G, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS. 1999; 13:1115-1122.
11. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831.
12. Schackman BR, Goldie SJ, Weinstein MC, et al. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001;91:1456-1463.
13. Beck E, Mandalia S, Gaudreault M, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS. 2004;18: 2411-2418.
14. Miners A, Sabin C, Trueman P, et al. Assessing the cost-effectiveness of highly active antiretroviral therapy for adults with HIV in England. HIV Med 2001;2:52-58.
15. Le Pen C, Rozenbaum W, Downs A, et al. Une analyse cout-efficacité du changement des schémas thérapeutiques dans le VIH depuis 1996 [in French]. Therapie. 2002;57:27-33.
16. Kowalik E, Jakubczyk M, Niewada M, et al. The cost-effectiveness of antiretroviral regimens containing protease inhibitors (PIS) or nonnucleoside reverse transcriptase inhibitors (NNRTI) in the treatment of HIVinfected individuals in Poland. Value Health. 2002;5:569. Abstract.
17. Lacey L, Youle M, Trueman P, et al. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective. Pharmacoeconomics. 1999;15(suppl 1):39-53.
18. Pinto JL, Lopez Lavid C, Badia X, et al. Análisis coste-efectividad del tratamiento antirretroviral de gran actividad en pacientes infectados por el VIH asintomáticos [in Spanish]. Med Clin (Barc). 2000;114(suppl 3):62-67.
19. Long L, Fox M, Rosen S. Cost of hospitalization for those presenting at an HIV treatment center in South Africa [THPE0859]. Paper presented at: XVIII International AIDS Conference, July 18-23, 2010; Vienna, Austria.
20. Smith de Cherif TK, Schoeman JH, Cleary S, et al. Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis. 2009;9:205.
21. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22:601-610.
22. Leisegang R, Cleary S, Hislop M, et al. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med 2009;6:e1000189.
23. Stearns BK, Evans DK, Lutung P, et al. Primary estimates of the costs of ART care at 5 AHF clinics in sub-Saharan Africa [MOPE0706]. Paper presented at: XVIIth International AIDS Conference, August 3-8, 2008; Mexico City, Mexico.
24. Harling G, Wood R. The evolving cost of HIV in South Africa-Changes in Health Care Cost With Duration on Antiretroviral Therapy for Public Sector Patients. J Acquir Immune Defic Syndr. 2007;45:348-354.
25. Marseille E, Kahn JG, Pietter C, et al. The cost-effectiveness of homebased provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy. 2009;7:229-243.
26. Cleary S, McIntyre D, Boulle A. The cost-effectiveness of antiretroviral treatment. Cost Eff Resour Alloc. 2006;4:20.
27. Thomas LS, Manning A, Holmes CB, et al. Comparative costs of inpatient care for HIV-infected and uninfected children and adults in Soweto, South Africa. J Acquir Immune Defic Syndr. 2007;46:410-416.
28. Martinson N, Mohapi L, Bakos D, et al. Costs of providing care for HIVinfected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009;50:327-330.
29. Long L, Rosen S, Sanne I. Stable outcomes and costs in South African patients' second year on antiretroviral treatment [abstract]. Paper presented at: International AIDS Economics Network Symposium, August 1-2, 2008; Cuernavaca, Mexico.
30. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008;13:1005-1015.
31. Chhagan V, Luiz J, Mohapi L, et al. The socioeconomic impact of antiretroviral treatment on individuals in Soweto, South Africa. Health Sociol Rev. 2008;17:95-105.
32. Golub J, Pronyk P, Mohapi L, et al. Isoniazide preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631-636.
33. Hanrahan CF, Golub JE, Mohapi L, et al. Body mass index and risk of tuberculosis and death. AIDS. 2010;24:1501-1508.
34. National Department of Health, Republic of South Africa. National Antiretroviral Treatment Guidelines. Pretoria, South Africa: Jacana Publishers; 2004.
35. World Health Organization. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Geneva, Switzerland; 2008.
36. Schafer JL. Analysis of Incomplete Multivariate Data. Boca Raton, FL: Chapman & Hall/CRC; 1997.
37. Health Systems Trust. The district health barometer 2008/09. Available at: http://www.hst.org.za/publications/district-health-barometer-200809. Accessed November 11, 2010.
38. National Department of Health. National Indicator dataset for South Africa. Pretoria, South Africa:National Department of Health; 2005.
39. Havlir DV, Getahun H, Sanne I, et al. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008;300:423-430.
40. Meyer-Rath G, Pillay Y, Blecher M, et al. Total cost and potential cost savings of the national antiretroviral treatment (ART) programme in South Africa 2010 to 2017 [WEAE0201]. Paper presented at: XVIII International AIDS Conference, July 18-23, 2010; Vienna, Austria.
41. Meyer-Rath G, Pillay Y, Blecher M, et al. The impact of a new reference price list mechanism for drugs on the total cost of the national antiretroviral treatment programme in South Africa 2011 to 2017 [621]. Paper presented at: South African AIDS Conference, June 7-10, 2011; Durban, South Africa.
42. Meintjes G, Rabie H, Wilkinson RJ, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med 2009;30:797-810.